CALC CalciMedica, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY34.5%
TTM EPS YoY152.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-763.3%
ROA-103.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets70.4%
Debt / equity0.00x
Current ratio4.96x
Interest coverage-14.15x
Cash quality & payout
Operating cash flow / net income1.20x
Accruals ratio21.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $15.23M | $14.48M |
| SG&A expense | $7.89M | $9.73M |
| Operating income | -$23.12M | -$24.20M |
| Interest expense | $1.42M | $0 |
| Pretax income | -$29.56M | -$13.70M |
| Income tax | $0 | $0 |
| Net income | -$29.56M | -$13.70M |
| EBITDA | -$23.07M | -$24.15M |
| EPS (basic) | -1.97 | -1.22 |
| EPS (diluted) | -1.97 | -1.22 |
| Weighted avg. shares (diluted) | 15.01M | 11.25M |
| Banking | ||
| Noninterest income | $713,000 | $1.01M |
| Balance sheet | ||
| Cash & equivalents | $11.52M | $7.93M |
| Short-term investments | $1.50M | $10.73M |
| Current assets | $13.53M | $19.66M |
| PP&E, net | $50,000 | $119,000 |
| Total assets | $13.59M | $19.79M |
| Current liabilities | $3.78M | $3.68M |
| Total liabilities | $20.23M | $5.38M |
| Shareholders' equity | -$6.64M | $14.41M |
| Shares outstanding | 3.09M | 13.48M |
| Cash flow statement | ||
| Operating cash flow | -$21.18M | -$21.15M |
| Capital expenditure | $28,000 | $8,000 |
| Free cash flow | -$21.21M | -$21.15M |
| Investing cash flow | $9.55M | -$4.42M |
| Financing cash flow | $15.21M | $27.97M |
| Depreciation & amortization | $46,000 | $58,000 |
| Stock-based compensation | $2.97M | $2.31M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.